The firm’s miserable run seems to be getting even worse in 2022, and every one of its U.S.-listed ETFs is down so far. The worst performer is the ARK Genomic Revolution ETF (ARKG) with a drop of 17% through Thursday. The best is ARK Israel Innovative Technology ETF (IZRL), which was down 5%.
Alongside ARKK, the other eight funds lost almost $50 million combined Wednesday. The settlement schedule for the products mean that flow data arrives with a one-day lag.
This article was provided by Bloomberg News.